Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma. Lifestyle preferences and baseline ...

The FDA approved zolbetuximab-clzb plus fluoropyrimidine- and platinum-containing chemotherapy for patients with CLDN18.2-positive locally advanced unresectable or metastatic HER2-negative gastric or ...

Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

Cilta-cel led to high response rates and a promising safety profile in a real-world population of patients with relapsed/refractory myeloma. A nurse practitioner discusses her role in caring for ...

After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression ...

Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer ...

Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer. Final results of the ARMANI trial demonstrated that switch maintenance therapy with ...

Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer ...